Regulation of peroxisome proliferator-activated receptor-α by MDM2

Toxicological Sciences

Volumn 108, Issue 1, 2009, Pages 48-58

  Gopinathan, Lakshmi ^a,b   Hannon, Daniel B ^b   Peters, Jeffrey M ^b   Vanden Heuvel, John P ^b  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

MDM2; Nuclear receptor; Peroxisome proliferator activated receptor alpha

Indexed keywords

CLOFIBRATE; LIGAND; LIPID; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PROTEIN MDM2; SMALL INTERFERING RNA; UBIQUITIN PROTEIN LIGASE E3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN COS1; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE TARGETING; GENETIC TRANSFECTION; HEPATOMA CELL; IN VITRO STUDY; LIPID METABOLISM; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; UBIQUITINATION; WILD TYPE;

ANALYSIS OF VARIANCE; ANIMALS; CELL LINE; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIPID METABOLISM; LIVER; MALE; MICE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PPAR ALPHA; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; PYRIMIDINES; RATS; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC;

MURINAE; MUS; RATTUS;

EID: 61349092992     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfn260     Document Type: Article

References (45)

1. Bhat, K. P., Itahana, K., Jin, A., and Zhang, Y. (2004). Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. EMBO J. 23, 2402-2412.
2. Blanquart, C., Barbier, O., Fruchart, J. C., Staels, B., and Glineur, C. (2002). Peroxisome proliferator-activated receptor alpha (PPARalpha) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes. J. Biol. Chem. 277, 37254-37259.
3. Bres, V., Kiernan, R. E., Linares, L. K., Chable-Bessia, C., Plechakova, O., Treand, C., Emiliani, S., Peloponese, J. M., Jeang, K. T., Coux, O., Scheffner, M., and Benkirane, M. (2003). A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter. Nat. Cell Biol. 5, 754-761.
4. Burns, K. A., and Vanden Heuvel, J. P. (2007). Modulation of PPAR activity via phosphorylation. Biochim. Biophys. Acta 1771, 952-960.
5. Cheung, C., Akiyama, T. E., Ward, J. M., Nicol, C. J., Feigenbaum, L., Vinson, C., and Gonzalez, F. J. (2004). Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha. Cancer Res. 64, 3849-3854.
6. Desvergne, B., Michalik, L., and Wahli, W. (2004). Be fit or be sick: Peroxisome proliferator-activated receptors are down the road. Mol. Endocrinol. 18, 1321-1332.
7. Duong, V., Boulle, N., Daujat, S., Chauvet, J., Bonnet, S., Neel, H., and Cavailles, V. (2007). Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents. Cancer Res. 67, 5513-5521.
8. Gaughan, L., Logan, I. R., Neal, D. E., and Robson, C. N. (2005). Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Res. 33, 13-26.
9. Gianni, M., Bauer, A., Garattini, E., Chambon, P., and Rochette-Egly, C. (2002). Phosphorylation by p38MAPK and recruitment of SUG-1 are required for RA-induced RAR gamma degradation and transactivation. EMBO J. 21, 3760-3769.
10. Gray, J. P., Davis, J. W., 2nd, Gopinathan, L., Leas, T. L., Nugent, C. A., and Vanden Heuvel, J. P. (2006). The ribosomal protein rpL11 associates with and inhibits the transcriptional activity of peroxisome proliferator-activated receptor-alpha. Toxicol. Sci. 89, 535-546.
11. Hays, T., Rusyn, I., Burns, A. M., Kennett, M. J., Ward, J. M., Gonzalez, F. J., and Peters, J. M. (2005). Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis 26, 219-227.
12. Hoivik, D. J., Qualls, C. W., Jr, Mirabile, R. C., Cariello, N. F., Kimbrough, C. L., Colton, H. M., Anderson, S. P., Santostefano, M. J., Morgan, R. J., Dahl, R. R., et al. (2004). Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence of cellular proliferation and oxidative stress in cynomolgus monkeys. Carcinogenesis 25, 1757-1769.
13. Hori, M., Shimazaki, J., Inagawa, S., and Itabashi, M. (2002). Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human breast cancer. Breast Cancer Res. Treat. 71, 77-83.
14. Huang, W., Zhang, J., Washington, M., Liu, J., Parant, J. M., Lozano, G., and Moore, D. D. (2005). Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. Mol. Endocrinol. 19, 1646-1653.
15. Issemann, I., and Green, S. (1990). Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-650.
16. Kinyamu, H. K., and Archer, T. K. (2003). Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression. Mol. Cell. Biol. 23, 5867-5881.
17. Kinyamu, H. K., Chen, J., and Archer, T. K. (2005). Linking the ubiquitin-proteasome pathway to chromatin remodeling/modification by nuclear receptors. J. Mol. Endocrinol. 34, 281-297.
18. Klaunig, J. E., Babich, M. A., Baetcke, K. P., Cook, J. C., Corton, J. C., David, R. M., DeLuca, J. G., Lai, D. Y., McKee, R. H., Peters, J. M., et al. (2003). PPARalpha agonist-induced rodent tumors: Modes of action and human relevance. Crit. Rev. Toxicol. 33, 655-780.
19. Knight, B., Yeap, B. B., Yeoh, G. C., and Olynyk, J. K. (2005). Inhibition of adult liver progenitor (oval) cell growth and viability by an agonist of the peroxisome proliferator activated receptor (PPAR) family member gamma, but not alpha or delta. Carcinogenesis 26 1782-1792.
20. Kulikov, R., Boehme, K. A., and Blattner, C. (2005). Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance. Mol. Cell. Biol. 25, 7170-7180.
21. Lee, S. S., Pineau, T., Drago, J., Lee, E. J., Owens, J. W., Kroetz, D. L., Fernandez-Salguero, P. M., Westphal, H., and Gonzalez, F. J. (1995). Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15, 3012-3022.
22. Levav-Cohen, Y., Haupt, S., and Haupt, Y. (2005). Mdm2 in growth signaling and cancer. Growth Factors 23, 183-192.
23. Lin, H. K., Wang, L., Hu, Y. C., Altuwaijri, S., and Chang, C. (2002). Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J. 21, 4037-4048.
24. Lohrum, M. A., Ludwig, R. L., Kubbutat, M. H., Hanlon, M., and Vousden, K. H. (2003). Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 3, 577-587.
25. Loughran, O., and La Thangue, N. B. (2000). Apoptotic and growth-promoting activity of E2F modulated by MDM2. Mol. Cell. Biol. 20, 2186-2197.
26. Ma, X., Stoffregen, D. A., Wheelock, G. D., Rininger, J. A., and Babish, J. G. (1997). Discordant hepatic expression of the cell division control enzyme p34cdc2 kinase, proliferating cell nuclear antigen, p53 tumor suppressor protein, and p21Waf1 cyclin-dependent kinase inhibitory protein after WY14,643 ([4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid) dosing to rats. Mol. Pharmacol. 51, 69-78.
27. Martin, K., Trouche, D., Hagemeier, C., Sorensen, T. S., La Thangue, N. B., and Kouzarides, T. (1995). Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375, 691-694.
28. Morimura, K., Cheung, C., Ward, J. M., Reddy, J. K., and Gonzalez, F. J. (2006). Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis. Carcinogenesis 27, 1074-1080.
29. Peters, J. M., Cattley, R. C., and Gonzalez, F. J. (1997). Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 18, 2029-2033.
30. Qi, J. S., Yuan, Y., Desai-Yajnik, V., and Samuels, H. H. (1999). Regulation of the mdm2 oncogene by thyroid hormone receptor. Mol. Cell. Biol. 19, 864-872.
31. Reid, G., Hubner, M. R., Metivier, R., Brand, H., Denger, S., Manu, D., Beaudouin, J., Ellenberg, J., and Gannon, F. (2003). Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol. Cell 11, 695-707.
32. Rininger, J. A., Goldsworthy, T. L., and Babish, J. G. (1997). Time course comparison of cell-cycle protein expression following partial hepatectomy and WY14,643-induced hepatic cell proliferation in F344 rats. Carcinogenesis 18, 935-941.
33. Rininger, J. A., Wheelock, G. D., Ma, X., and Babish, J. G. (1996). Discordant expression of the cyclin-dependent kinases and cyclins in rat liver following acute administration of the hepatocarcinogen [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY14,643). Biochem. Pharmacol. 52, 1749-1755.
34. Rochette-Egly, C. (2005). Dynamic combinatorial networks in nuclear receptor-mediated transcription. J. Biol. Chem. 280, 32565-32568.
35. Sengupta, S., and Wasylyk, B. (2004). Physiological and pathological consequences of the interactions of the p53 tumor suppressor with the glucocorticoid, androgen, and estrogen receptors. Ann. N. Y. Acad. Sci. 1024, 54-71.
36. Shen, T., Horwitz, K. B., and Lange, C. A. (2001). Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. Mol. Cell. Biol. 21, 6122-6131.
37. Simbula, G., Pibiri, M., Sanna, L., Cossu, C., Molotzu, F., Columbano, A., and Ledda-Columbano, G. M. (2004). The peroxisome proliferator BR931 kills FaO cells by p53-dependent apoptosis. Life Sci. 75, 271-286.
38. Tien, E. S., Davis, J. W., and Vanden Heuvel, J. P. (2004). Identification of the CREB-binding protein/p300-interacting protein CITED2 as a peroxisome proliferator-activated receptor alpha coregulator. J. Biol. Chem. 279, 24053-24063.
39. Tien, E. S., Gray, J. P., Peters, J. M., and Vanden Heuvel, J. P. (2003). Comprehensive gene expression analysis of peroxisome proliferator-treated immortalized hepatocytes: Identification of peroxisome proliferator-activated receptor alpha-dependent growth regulatory genes. Cancer Res. 63, 5767-5780.
40. Tien, E. S., Hannon, D. B., Thompson, J. T., and Vanden Heuvel, J. P. (2006). Examination of ligand-dependent coactivator recruitment by peroxisome proliferator-activated receptor-alpha (PPARalpha). PPAR Res. 2006, 69612.
41. Uchida, C., Miwa, S., Kitagawa, K., Hattori, T., Isobe, T., Otani, S., Oda, T., Sugimura, H., Kamijo, T., Ookawa, K., et al. (2005). Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation. EMBO J. 24, 160-169.
42. Wallace, A. D., and Cidlowski, J. A. (2001). Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J. Biol. Chem. 276, 42714-42721.
43. Yang, Q., Nagano, T., Shah, Y., Cheung, C., Ito, S., and Gonzalez, F. J. (2008). The PPAR alpha-humanized mouse: A model to investigate species differences in liver toxicity mediated by PPAR alpha. Toxicol. Sci. 101, 132-139.
44. Zhang, Y., Wolf, G. W., Bhat, K., Jin, A., Allio, T., Burkhart, W. A., and Xiong, Y. (2003). Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol. Cell Biol. 23, 8902-8912.
45. Zhao, B. X., Chen, H. Z., Lei, N. Z., Li, G. D., Zhao, W. X., Zhan, Y. Y., Liu, B., Lin, S. C., and Wu, Q. (2006). p53 mediates the negative regulation of MDM2 by orphan receptor TR3. EMBO J. 25, 5703-5715.